North Star Asset Management Inc. Sells 2,098 Shares of Eli Lilly and Company $LLY

North Star Asset Management Inc. lessened its stake in Eli Lilly and Company (NYSE:LLY) by 13.4% in the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 13,508 shares of the company’s stock after selling 2,098 shares during the quarter. North Star Asset Management Inc.’s holdings in Eli Lilly and Company were worth $10,307,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other hedge funds also recently bought and sold shares of the company. Laurel Wealth Advisors LLC increased its position in Eli Lilly and Company by 78,621.2% during the second quarter. Laurel Wealth Advisors LLC now owns 11,552,336 shares of the company’s stock valued at $9,005,392,000 after acquiring an additional 11,537,661 shares during the last quarter. Norges Bank bought a new stake in shares of Eli Lilly and Company during the 2nd quarter valued at about $8,827,714,000. Vanguard Group Inc. increased its position in shares of Eli Lilly and Company by 1.5% during the 2nd quarter. Vanguard Group Inc. now owns 80,407,430 shares of the company’s stock valued at $62,680,004,000 after purchasing an additional 1,183,038 shares during the last quarter. Franklin Resources Inc. lifted its stake in shares of Eli Lilly and Company by 13.4% in the 2nd quarter. Franklin Resources Inc. now owns 4,766,865 shares of the company’s stock worth $3,715,913,000 after purchasing an additional 564,736 shares during the period. Finally, Canada Pension Plan Investment Board boosted its holdings in shares of Eli Lilly and Company by 87.2% in the second quarter. Canada Pension Plan Investment Board now owns 1,152,281 shares of the company’s stock worth $898,238,000 after buying an additional 536,679 shares during the last quarter. Institutional investors own 82.53% of the company’s stock.

Key Stories Impacting Eli Lilly and Company

Here are the key news stories impacting Eli Lilly and Company this week:

• Positive Sentiment: Head‑to‑head trial news showing Novo’s next‑gen obesity candidate underperformed Lilly’s tirzepatide has strengthened expectations that Lilly will retain market share in the high-growth weight‑loss category; that data triggered earlier upside in LLY. Trial Readout Lifts Lilly
• Positive Sentiment: Lilly launched an FDA‑cleared multi‑dose KwikPen for Zepbound (tirzepatide), giving patients a more convenient monthly device at the same self‑pay price — a commercial move intended to improve adherence and retention. Zepbound KwikPen Launch
• Positive Sentiment: Wall Street remains constructive on LLY’s longer‑term outlook (Goldman and other analysts keep Buy/Outperform calls and elevated price targets), supporting the stock’s valuation against the sector noise. Analyst Support
• Neutral Sentiment: Early clinical work showing benefit of combining Zepbound with other therapies (e.g., Taltz) and investor commentary on retention strategies (multi‑dose pen) add incremental optionality but are not immediate revenue drivers. Pipeline/Combo Data
• Negative Sentiment: Nuevo pricing shock — Novo Nordisk announced U.S. list price cuts of up to ~50% for Ozempic/Wegovy (to ~$675/month starting 2027). That move has rattled the sector, and LLY shares have slipped as investors reassess pricing dynamics and potential margin/market‑share impacts across GLP‑1s. Novo Price Cut Hits Stocks
• Negative Sentiment: Broader competition and pricing pressure could compress realized prices or accelerate payer negotiations over time, a structural risk to growth if competitors follow price cuts or insurers demand steeper discounts. Price Competition Risk

Eli Lilly and Company Stock Performance

Shares of NYSE:LLY opened at $1,042.68 on Wednesday. The company has a current ratio of 1.58, a quick ratio of 1.19 and a debt-to-equity ratio of 1.54. Eli Lilly and Company has a 12 month low of $623.78 and a 12 month high of $1,133.95. The company has a market capitalization of $983.62 billion, a price-to-earnings ratio of 45.43, a PEG ratio of 1.23 and a beta of 0.39. The firm’s 50-day moving average is $1,054.49 and its 200 day moving average is $923.72.

Eli Lilly and Company (NYSE:LLY) last announced its earnings results on Wednesday, February 4th. The company reported $7.54 earnings per share (EPS) for the quarter, beating the consensus estimate of $7.48 by $0.06. The business had revenue of $19.29 billion during the quarter, compared to analyst estimates of $17.85 billion. Eli Lilly and Company had a return on equity of 102.94% and a net margin of 31.66%.The company’s revenue for the quarter was up 42.6% compared to the same quarter last year. During the same quarter in the previous year, the business earned $5.32 earnings per share. Eli Lilly and Company has set its FY 2026 guidance at 33.500-35.000 EPS. Research analysts predict that Eli Lilly and Company will post 23.48 EPS for the current year.

Eli Lilly and Company Increases Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Tuesday, March 10th. Shareholders of record on Friday, February 13th will be given a $1.73 dividend. This is a boost from Eli Lilly and Company’s previous quarterly dividend of $1.50. The ex-dividend date of this dividend is Friday, February 13th. This represents a $6.92 annualized dividend and a yield of 0.7%. Eli Lilly and Company’s dividend payout ratio is currently 30.15%.

Wall Street Analyst Weigh In

A number of analysts have commented on the stock. Cantor Fitzgerald upped their target price on shares of Eli Lilly and Company from $985.00 to $1,205.00 and gave the company an “overweight” rating in a report on Thursday, February 5th. JPMorgan Chase & Co. upped their price objective on Eli Lilly and Company from $1,150.00 to $1,300.00 and gave the stock an “overweight” rating in a research note on Thursday, February 5th. Barclays assumed coverage on shares of Eli Lilly and Company in a research report on Thursday, February 19th. They issued an “overweight” rating and a $1,350.00 price target on the stock. Bank of America lowered their price objective on shares of Eli Lilly and Company from $1,286.00 to $1,268.00 and set a “buy” rating for the company in a research report on Monday, December 15th. Finally, The Goldman Sachs Group set a $1,260.00 target price on shares of Eli Lilly and Company in a report on Thursday, February 5th. Two research analysts have rated the stock with a Strong Buy rating, twenty-three have given a Buy rating and five have issued a Hold rating to the stock. According to data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus price target of $1,229.33.

Eli Lilly and Company Profile

Eli Lilly and Company (NYSE: LLY) is a global pharmaceutical company founded in 1876 and headquartered in Indianapolis, Indiana. The company researches, develops, manufactures and commercializes a broad range of medicines and therapies for patients worldwide. Eli Lilly maintains operations and commercial presence across North America, Europe, Asia and other regions, serving both developed and emerging markets. The company has been led in recent years by President and Chief Executive Officer David A.